Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963211 | 0.83 | APLNR (0.35) | CYP11B2CYP11B1PIK3R1PIK3CA | |
| SCHEMBL22012108 | 0.80 | CYP11B2 (0.37) | CYP11B2CYP11B1PIK3R1PIK3CAHSD11B1 | |
| SCHEMBL24978419 | 0.79 | HSD11B1 (0.45) | HSD11B1 | |
| SCHEMBL22021471 | 0.76 | HSD11B1 (0.33) | CYP11B2HSD11B1 | |
| SCHEMBL22021481 | 0.75 | PIK3CA (0.46) | CYP11B2CYP11B1PIK3R1PIK3CA | |
| SCHEMBL22012109 | 0.74 | PIK3R1 (0.34) | CYP11B2CYP11B1PIK3R1PIK3CA | |
| SCHEMBL22012105 | 0.73 | APLNR (0.55) | CYP11B2CYP11B1PIK3R1PIK3CA | |
| SCHEMBL24978777 | 0.71 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL24773026 | 0.70 | ALDH1A1 (0.47) | HSD11B1 | |
| SCHEMBL21962669 | 0.70 | S1PR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP11B2 72/4885CYP11B1 103/4885PIK3R1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.